Antiseizure Medications - Clobazam Products
Customize your policy alerts
Sign up for Cigna Policy IP0106 alerts
Get alerted when Policy IP0106 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and medical-necessity coverage for clobazam products, including Onfi, generic clobazam, and Sympazan, for commercially insured members. It applies to initial and continuation therapy for Lennox-Gastaut syndrome, Dravet syndrome, and treatment-refractory seizures or epilepsy.
The policy title was updated from "Clobazam" to "Antiseizure Medications - Clobazam Products."
A Preferred Product Table was added for employer plans.
The October 29, 2026 review and November 15, 2026 effective-date update made no criteria changes.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.